Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer ; volume:14 ; number:1 ; day:6 ; month:8 ; year:2024 ; pages:1-9 ; date:12.2024
Scientific reports ; 14, Heft 1 (6.8.2024), 1-9, 12.2024
- Creator
-
Claus, Jonas
Smet, Dieter De
Breyne, Joke
Wesolowski, Janusz
Himpe, Ulrike
Demedts, Ingel
Martens, Geert A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-68350-6
- URN
-
urn:nbn:de:101:1-2410262118131.893993086804
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Claus, Jonas
- Smet, Dieter De
- Breyne, Joke
- Wesolowski, Janusz
- Himpe, Ulrike
- Demedts, Ingel
- Martens, Geert A.
- SpringerLink (Online service)
Other Objects (12)
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Exosomes: a new perspective in EGFR-mutated lung cancer
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
EGFR-TKIs resistance via EGFR-independent signaling pathways
Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC
Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study
Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with Icotinib: phase 2 multicenter trial result
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Exosomes: a new perspective in EGFR-mutated lung cancer
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
EGFR-TKIs resistance via EGFR-independent signaling pathways
Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC
Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study
Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with Icotinib: phase 2 multicenter trial result
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Exosomes: a new perspective in EGFR-mutated lung cancer
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
EGFR-TKIs resistance via EGFR-independent signaling pathways
Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC
Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study